Topic
10 stories from Planck Standard. Latest: October 16, 2026.
The cases, obtained by CBS News under FOIA, appear to be the first public U.S. accounts linking illicit retatrutide to a death, though the details are unverified.
Pharmaceutical companies bet on new approaches to crack into the lucrative weight loss market currently controlled by two industry giants.
The pharmaceutical giants are preparing to compete for senior customers as Medicare prepares to cover oral versions of popular weight-loss medications.
Eli Lilly's retatrutide injection shows results comparable to gastric bypass surgery among heaviest patients after 80 weeks of treatment.
Eli Lilly's GLP-1 generated $8.7 billion in Q1 sales versus Merck's $7.9 billion, ending Keytruda's three-year reign atop global drug-revenue rankings.
Pharmaceutical giant raises full-year outlook by $2 billion as Zepbound and Mounjaro prescriptions skyrocket, with 20,000 patients now taking new pill Foundayo.
Novartis, Amgen, and Eli Lilly target lipoprotein(a) in race to develop next generation of cardiovascular treatments.
The pharmaceutical giant bets on revolutionary in vivo CAR-T technology that reprograms patients' immune cells inside the body. The deal represents Lilly's largest acquisition in years.
Orforglipron delivered 12.4% average body weight loss in trials and was approved in just 50 days — the fastest new drug approval since 2002 — at per month.
Foundayo approval comes three months after Novo Nordisk's oral Wegovy hit market, intensifying competition in rapidly growing obesity treatment sector.